American National Registered Investment Advisor Inc. maintained its position in Pfizer, Inc. (NYSE:PFE) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 77,749 shares of the biopharmaceutical company’s stock at the end of the second quarter. Pfizer makes up about 1.1% of American National Registered Investment Advisor Inc.’s holdings, making the stock its 12th largest position. American National Registered Investment Advisor Inc.’s holdings in Pfizer were worth $2,612,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Asset Planning Services Ltd. boosted its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. D. Scott Neal Inc. boosted its position in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Orrstown Financial Services Inc. boosted its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new position in shares of Pfizer during the first quarter worth approximately $121,000. Finally, Cascade Investment Advisors Inc. boosted its position in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares during the period. 69.95% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Pfizer, Inc. (NYSE:PFE) opened at 33.48 on Friday. The stock has a market cap of $199.80 billion, a price-to-earnings ratio of 28.18 and a beta of 1.01. The stock’s 50 day moving average price is $33.20 and its 200 day moving average price is $33.25. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $37.39.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.02. The business had revenue of $12.78 billion during the quarter, compared to analysts’ expectations of $13.09 billion. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. The business’s revenue was down 1.7% on a year-over-year basis. During the same period last year, the firm posted $0.67 earnings per share. Equities research analysts anticipate that Pfizer, Inc. will post $2.55 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.82%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is presently 108.48%.

TRADEMARK VIOLATION NOTICE: “Pfizer, Inc. (NYSE:PFE) Stake Maintained by American National Registered Investment Advisor Inc.” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/07/22/pfizer-inc-nysepfe-stake-maintained-by-american-national-registered-investment-advisor-inc.html.

A number of equities analysts recently issued reports on the company. Citigroup Inc. cut Pfizer from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $38.00 to $31.00 in a report on Tuesday, May 16th. Sanford C. Bernstein reaffirmed a “buy” rating and set a $35.00 target price on shares of Pfizer in a research report on Friday, March 24th. Barclays PLC reaffirmed a “buy” rating and set a $38.00 target price on shares of Pfizer in a research report on Wednesday, May 3rd. Credit Suisse Group AG lowered Pfizer from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $38.00 to $36.00 in a research report on Thursday. Finally, Jefferies Group LLC reissued a “neutral” rating and issued a $34.00 price target on shares of Pfizer in a research report on Friday, June 16th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and ten have issued a buy rating to the company. Pfizer presently has an average rating of “Hold” and an average price target of $37.68.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.